RxDoctor Payments Data

Christopher Evans, MD

Infectious Disease · Portland, ORNPI 1811160468

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Viiv Healthcare Company.

$66in general payments, 2019–2025

Across 1 payment — averaging $66.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$66
$212,135in research payments, 2019–2025

Across 75 payments — averaging $2828.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$140K
  • Viiv Healthcare Company$73K

What the payments were for

  • Food & beverage$66100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company1$66

How this compares

$66 in reported general payments places this provider in the 55th percentile of 90 infectious disease providers in Oregon.

See all infectious disease providers in Oregon

Medicare billing

Part B allowed, 2024
$7,133
Medicare patients
46
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala332$1,371,075
TivicayDolutegravir Sodium143$428,345
DescovyEmtricitabine/Tenofov Alafenam102$252,684
GenvoyaElviteg/Cob/Emtri/Tenof Alafen44$226,093
TriumeqAbacavir/Dolutegravir/Lamivudi60$223,284
PrezcobixDarunavir/Cobicistat85$217,783
RukobiaFostemsavir Tromethamine23$195,379
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf33$188,253
OdefseyEmtricitab/Rilpiviri/Tenof Ala26$133,776
IsentressRaltegravir Potassium40$97,319
DovatoDolutegravir Sodium/Lamivudine26$92,972
PifeltroDoravirine21$54,433
Maraviroc25$38,167
XifaxanRifaximin13$36,941
EliquisApixaban46$29,307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Triumeq, Rukobia, Dovato$66$939,980252 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 90 infectious disease providers in Oregon.

Other infectious disease in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →